← Back to Analyst Consensus 
CRNX Hold
Crinetics Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 28, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Jul 8, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Jul 8, 2026 | Evercore ISI Group | downgrade | Outperform → In-Line | — | 58% |
| Jul 7, 2026 | Jones Trading | downgrade | Buy → Hold | — | 50% |
| Jul 7, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| Jul 7, 2026 | Oppenheimer | downgrade | Outperform → Perform | — | 52% |
| Jul 7, 2026 | Cantor Fitzgerald | downgrade | Overweight → Neutral | — | 50% |
| Jul 7, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Jul 7, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Jul 2, 2026 | UBS | initiate | — → Buy | — | 54% |
| Jun 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 11, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| May 15, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| May 11, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| May 8, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Apr 28, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Mar 2, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Jan 12, 2026 | Goldman Sachs | upgrade | Neutral → Buy | $67 | 54% |
| Jan 8, 2026 | Citizens | maintain | Market Outperform → Market Outperform | $105 | 47% |
| Jan 6, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $80 | 54% |
| Nov 7, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $108 | 47% |
| Sep 30, 2025 | Oppenheimer | maintain | Outperform → Outperform | $87 | 52% |
| Sep 29, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $77 | 54% |
| Sep 29, 2025 | Leerink Partners | maintain | Outperform → Outperform | $88 | 51% |
| Sep 26, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $40 | 54% |
| Sep 26, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $143 | 53% |
| Sep 26, 2025 | Baird | maintain | Outperform → Outperform | $62 | 55% |
| Sep 24, 2025 | JP Morgan | maintain | Overweight → Overweight | $52 | 54% |
| Aug 11, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $86 | 53% |
| Jun 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $81 | 44% |
| Mar 25, 2025 | Stifel | initiate | — → Buy | $60 | 53% |
| Feb 28, 2025 | Citizens Capital Markets | maintain | Market Outperform → Market Outperform | $91 | 49% |
| Feb 4, 2025 | Wolfe Research | initiate | — → Peer Perform | $0 | 54% |
| Jan 22, 2025 | Jefferies | upgrade | Hold → Buy | $55 | 52% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $81 | 44% |
| Dec 16, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $87 | 53% |
| Nov 14, 2024 | Citigroup | maintain | Buy → Buy | $74 | 54% |
| Nov 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $81 | 44% |
| Sep 27, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $80 | 53% |
| Sep 16, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $90 | 50% |
| Aug 9, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $69 | 44% |
| Aug 9, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $73 | 52% |
| Jul 9, 2024 | JP Morgan | maintain | Overweight → Overweight | $54 | 54% |
| Jul 2, 2024 | Piper Sandler | maintain | Overweight → Overweight | $97 | 54% |
| Jun 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $60 | 44% |
| Jun 4, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $80 | 53% |
| Jun 4, 2024 | Oppenheimer | maintain | Outperform → Outperform | $74 | 52% |
| Jun 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $60 | 44% |
| May 23, 2024 | Baird | maintain | Outperform → Outperform | $62 | 55% |
| May 23, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $70 | 54% |
Price Target Trend
Jun 18, 2026 Oct 27, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days